The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up

Abstract

AbstractBackgroundThe routine assessment of progesterone receptor (PR) expression in breast cancer (BC) remains controversial. This study aimed to evaluate the role of PR expression in luminal BC, with emphasis on the definition of positivity and its prognostic significance as compared to Ki67 expression.MethodsA large cohort (n = 1924) of estrogen receptor (ER)‐positive/HER2‐negative BC was included. PR was immunohistochemically (IHC) stained on full face sections and core needle biopsies (CNB) where the optimal scoring cutoff was evaluated. In addition, the association of PR with other clinicopathological factors, cellular proliferation, disease outcome, and response to adjuvant therapy were analyzed.ResultsAlthough several cutoffs showed prognostic significance, the optimal cutoff to categorize PR expression into two clinically distinct prognostic groups on CNB was 10%. PR negativity showed a significant association with features of aggressive tumor behavior and poor outcome. Multivariate analyses indicated that the association between PR negativity and poor outcome was independent of tumor grade, size, node stage, and Ki67. PR negativity showed independent association with shorter survival in patients who received endocrine therapy whereas Ki67did not.ConclusionPR IHC expression provides independent prognostic value superior to Ki67. Routine assessment of PR expression in BC using 10% cutoff in the clinical setting is recommended.Plain Language Summary In this study, we have established an optimal approach to determine the prognostic value of progesterone receptor expression in estrogen receptor‐positive breast cancer patients. To do this, the levels of progesterone receptor were measured in a large cohort of estrogen receptor‐positive breast cancer patients. We have refined the definition of progesterone receptor positivity in estrogen receptor‐positive breast cancer. We show that progesterone receptor expression adds prognostic and predictive value of endocrine therapy in estrogen receptor‐positive breast cancer patients, and our results show that the absence of progesterone receptor is associated with poorer outcomes independent of tumor grade, size, node stage, and Ki67 expression.